$12.850
-0.407 (-3.17%)Zum Schluss
KLRA im Vergleich zur Peergroup
In the context of the broader market, KLRA competes directly with industry leaders such as ANIP and URGN. With a market capitalization of $1.67B, it holds a leading position in the sector. When comparing efficiency, KLRA's gross margin of N/A stands against ANIP's 54.97% and URGN's 90.93%. Such benchmarking helps identify whether Kailera Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von Kailera Therapeutics Inc
Kailera has shown a significant increase in current assets, rising from 530,315,000 USD in Q1 2026 to 929,167,000 USD in Q2 2026, indicating improved liquidity. However, the company is still facing large net losses, with EPS reported at -1.09 for Q2 2026.
Financials
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.